BBT takes possession of the first biodevelopment building on the Babraham Research Campus


16-12-2004

Babraham Bioscience Technologies Ltd (BBT) has taken possession of the first new commercial building on the Babraham Research Campus, just one year since ground was broken.

The partially-fitted bioscience research and development facility (BioDevelopment Building) was handed over on 10th December by the contractors, SDC: ahead of schedule and within budget. It is envisaged that the first tenant will move in during March 2005.



Dr David Hardman, CEO of BBT said, 'We're pleased with the facilities, in terms of style, design and utility. The new building, to be named 'Minerva', after the Roman goddess of wisdom, provides grow-on units for early stage bioventures as they make the move out of incubation facilities. We see this and future buildings as part of our innovative approach to supporting start-up and early stage biomedical ventures.'



BBT takes possession of the first biodevelopment building on the Babraham Research CampusDr Hardman believes Minerva, the first of three BioDevelopment Buildings, will act as a catalyst to promote knowledge transfer: 'The Babraham Research Campus brings together the Babraham Institute's world-class science base with innovative ventures exploiting new biotechnologies relating to human healthcare. This creates a unique continuum to support the knowledge transfer process.'



BBT's BioDevelopment buildings provide flexible laboratory and office accommodation. Fixtures and fittings specified by the tenant will be added to the generic fit-out, thus meeting the tenant's needs whilst minimizing the time it takes to make the facility ready for occupation. This will take a maximum of 12 weeks from agreeing formal terms. Full fit-out costs can be covered as rent, enabling bioventures to focus their funds on delivering their business plans rather than tying them up in premises capital.



Dr Richard Dyer, Director of the Babraham Institute and Chairman of BBT, adds: 'These developments, and other initiatives - such as Babraham BioConcepts - will ensure the Campus is at the heart of the southern Cambridge biotech cluster, playing an important role in nurturing bioventures to deliver biomedical discovery, innovation and product development.'











Babraham Bioscience Technologies Ltd
is the wholly owned subsidiary and trading arm of the Babraham Institute and is the managing company for the Bioincubator, BioConcepts and the commercial development of the Babraham Research Campus. BioConcepts is a technology accelerator assisting the establishment of new bioventures, and thus supporting the translation of new biotechnologies into investment-ready opportunities. BioConcepts is part-funded by the East of England Development Agency as a Regional Enterprise Hub.



Website: www.babraham.com



The Babraham Institute is a charitable organisation, sponsored by the Biotechnology and Biological Sciences Research Council. The Institute's research focuses on the mechanisms of cell signalling and gene regulation which underlie normal cellular processes and functions, and on how their failure or abnormality may lead to disease.



As such Institute scientists are striving to find cures for conditions where there is currently no treatment or where the existing treatment is not fully effective or causes serious side effects. Babraham is located six miles south-east of Cambridge.



Website: www.babraham.ac.uk



*******



Contact details



Dr David J Hardman, Chief Executive Officer

Babraham Bioscience Technologies Ltd

Tel: +44 (0)1223 496205

Fax: +44 (0)1223 496020

Email: dj.hardman@babraham.co.uk

To read more information, click here.

The Institute is an independent charitable life sciences research institute, strategically funded by the Biotechnology and Biological Sciences Research Council.

Babraham Institute